FUJIFILM Diosynth Biotechnologies confirms £400 million investment in UK

Japanese contract development and manufacturing organization (CDMO) FUJIFILM Diosynth Biotechnologies has confirmed a £400 million ($529 million) planned investment package at its UK facility in Billingham, Teesside.

This investment package more than doubles the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the UK and is expected to create up to 350 highly-skilled jobs. The new facilities are expected to be operational by late 2023.

The new multi-modal campus will include two new state-of-the-art facilities (a viral gene therapy GMP facility and a GMP mammalian cell culture facility) and is part of a 90 billion yen ($850 million) global capital investment package initially outlined by FUJIFILM Corporation (TYO: 4901) in June 2021.